

miRNA-155在急性髓性白血病不同阶段中的表达及临床意义

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年02期 页码: 316-318 栏目: 论著 (造血器·淋巴系肿瘤) 出版日期: 2018-12-08

Title: Expression of miRNA-155 in acute myeloid leukemia and its clinical significance

作者: 罗自勉; 周丹; 周新伏; 尹亚飞; 谭振清; 刘平; 金娟; 朱凯波; 霍中军; 杨文群
湘潭市中心医院血液科,湖南 湘潭 411100

Author(s): Luo Zimian; Zhou Dan; Zhou Xinfu; Yin Yafei; Tan Zhenqing; Liu Ping; Jin Juan; Zhu Kaibo; Huo Zhongjun; Yang Wenqun
Department of Hematology,Xiangtan Central Hospital,Hunan Xiangtan 411100,China.

关键词: 血浆miRNA-155; 急性髓性白血病; 不同阶段

Keywords: plasama miRNA-155; acute myeloid leukemia; different disease phase

分类号: R733.71

DOI: 10.3969/j.issn.1672-4992.2019.02.034

文献标识码: A

摘要: 目的:分析血浆miRNA-155在急性髓性白血病不同阶段中的表达。方法:选取急性髓性白血病21例和健康对照组20例,抽取空腹静脉血,离心后取血浆,直接扩增目的miRNA,并反转录为cDNA,qRT-PCR方法检测血浆miRNA-155的表达。结果:急性髓性白血病初诊组血浆miRNA-155的表达显著高于正常对照组和缓解组,初诊组与未缓解组之间无统计学差异,缓解组与未缓解组之间有统计学差异。结论:血浆miRNA-155在急性髓性白血病不同阶段中的表达不同,有一定的诊断、治疗、预后评估意义。

Abstract: Objective:To investigate the level of miRNA-155 in plasma of acute myeloid leukemia (AML) patients at different disease phase.Methods:21 AML patients and 20 healthy controls were enrolled in this study and their plasma samples were acquired by density gradient centrifugation.miRNA in plasma was firstly reversed to cDNA and then real-time quantitative PCR (qPCR) was used to detect the expression level of miRNA-155.Results:The expression of miR-155 was significantly higher in de novo AML group than that in remission group and healthy control group.There was no significant difference between de novo AML group and non-remission group,while significant difference was observed between remission group and non-remission group.Conclusion:miRNA-155 in plasma from AML patients at different disease phase is at different expression level,and is useful for diagnosis,treatment and prognosis evaluation.

参考文献/REFERENCES

- [1] Raghuvanshi S,Karnati HK,Sarvothaman S,et al.microRNAs:Key players in hematopoiesis [J] .Adv Exp Med Biol,2015,887:171-211.
- [2] Zhang ZN.Diagnostic and therapeutic criteria for hematopathy DSM-III [J] .Beijing, Science Press, 2007:106-115. [张之南, 主编.血液病诊断及疗效标准 [J] .第三版,北京:科学出版社,2007:106-115.]
- [3] Elton TS,Selemon H,Elton SM,et al.Regulation of the MIR155 host gene in physiological and pathological processes [J] .Gene,2013,532(1):1-12.
- [4] Li XD,Li XM,Gu JW,et al.MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway [J] .Eur Rev Med Pharmacol Sci,2017,21(22):5153-5159.
- [5] Zhang X,Li M,Zuo K,et al.Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/B-catenin signaling,2013,98(8):E1305-E1313.
- [6] Ovcharenko D,Kelnar K,Johnson C,et al.Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway [J] .Cancer Res,2007,67(22):10782-10788.
- [7] Marcucci G,Radmacher MD,Maharry K,et al.microRNA expression in cytogenetically normal acute myeloid leukemia [J] .N Engl J Med,2008,358(18):1919-1928.
- [8] Marcucci G,Maharry K,Radmacher MD,et al.Prognostic significance of, and gene and microRNA expression signatures associated with,CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features:A cancer and leukemia group B study [J] .J Clin Oncol,2008,26(31):5078-5087.
- [9] Lutherborrow M,Bryant A,Jayaswal V,et al.Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation [J] .Am J

Hematol,2011,86(1):2-11.

[10] Tian M,Tan SQ,Liu JR, et al,Analysis of differential expression profiles of exosomal microRNA in acute myeloid leukemia through high-throughput sequencing technologies [J] .Chin J Biochem Mol Biol,2017,33(2):138-149. [田淼, 谭三勤, 刘静茹, 等.高通量测序技术分析急性髓性白血病血浆外泌体微RNA表达谱差异 [J] .中国生物化学与分子生物学报,2017,33(2):138-149.]

[11] Hu XL,Tang AP.Expression and clinical significance of microRNA-155 in acute myeloid leukemia [J] .Chinese Journal of Practical Hematology,2016, 32 (1) :980-984. [胡献丽, 汤爱萍.microRNA-155在急性髓性白血病中的表达及临床意义 [J] .中国实用血液学杂志, 2016, 32 (1) :980-984.]

[12] Khalife J,Radomska HS,Santhanam R,et al.Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924(Pevonedistat) in FLT3-ITD acute myeloid leukemia [J] .Leukemia,2015,29(10):1981-1992.

[13] Marcucci G,Maharry KS,Metzeler KH,et al.Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia:miR-155 upregulation independently identifies high-risk patients [J] .J Clin Oncol,2013,31(17):2086-2093.

[14] Yang TH, Shen XM,Lu ZX,et al.Risk factors for misdiagnosis of acute leukemia in different grade hospitals [J] .Clinical Misdiagnosis & Mistherapy,2001,1 (1) : 5-7. [杨同华, 沈晓梅, 陆智祥, 等.急性白血病在不同级别医院误诊的危险因素分析 [J] .临床误诊误治, 2001,1 (1) : 5-7.] [15] Hornick NI,Huan J,Doron B,et al.Serum exosome microRNA as a minimally-invasive early biomarker of AML [J] .Sci Rep,2015,5:11295.

[16] Sohn W,Kim J,Kang SH,et al.Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma [J] .Exp Med,2015,47:184.

备注/Memo: 湘潭市医学会科技计划项目(编号: 2014
[5] 号)

更新日期/Last Update: 1900-01-01